NCM · Financial Statements

Cue Biopharma, Inc. (CUE) Financial Statements

$18.66 NCM: CUE Market Cap $135.55M

Cue Biopharma, Inc. most recently reported annual revenue of $27.0M, a net loss of $27.0M. Revenue grew at an average annual rate of 55.2% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Cue Biopharma, Inc.: net profit was positive in 0 of 10 reported years; operating margin moved from -3386.7% to -96.6%, a shift of +3290.2 percentage points; the most recent year shows a net loss of $27.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$1.0M$3.0M$3.0M$15.0M$1.0M$5.0M$9.0M$27.0M
Operating Expenses$8.0M$23.0M$40.0M$40.0M$48.0M$59.0M$54.0M$58.0M$51.0M$54.0M
Operating Profit$-8.0M$-23.0M$-39.0M$-37.0M$-45.0M$-44.0M$-53.0M$-52.0M$-41.0M$-27.0M
Operating Margin0.0%0.0%-3386.7%-1063.2%-1428.0%-292.6%-4275.1%-949.9%-446.9%-96.6%
Other Income$0$0$1.0M$0$0$0$0$1.0M$1.0M$0
Interest$0$0$0$0$0$0$1.0M$1.0M$1.0M$0
Depreciation$0$0$1.0M$1.0M$1.0M$-2.0M$2.0M$3.0M$2.0M$3.0M
Profit Before Tax$-8.0M$-23.0M$-38.0M$-36.0M$-45.0M$-44.0M$-53.0M$-51.0M$-41.0M$-26.0M
Tax$0$0$-2.2M$-1.1M$-460,000$-1.1M$0$0$0$-1.9M
Net Profit$-8.0M$-23.0M$-39.0M$-37.0M$-45.0M$-44.0M$-53.0M$-51.0M$-41.0M$-27.0M
EPS$-11.10$-33.90$-58.20$-49.80$-46.80$-42.30$-44.70$-33.30$-21.60$-8.40
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$2.0M$2.0M$2.0M$3.0M$3.0M$2.0M$0$3.0M$2.0M$22.0M$6.0M$8.0M
Operating Expenses$14.0M$16.0M$14.0M$13.0M$12.0M$11.0M$13.0M$12.0M$10.0M$20.0M$11.0M$96.0M
Operating Profit$-11.0M$-14.0M$-13.0M$-10.0M$-9.0M$-10.0M$-12.0M$-9.0M$-8.0M$2.0M$-5.0M$-88.0M
Operating Margin-543.8%-759.6%-737.8%-390.6%-264.2%-611.2%-2921.4%-292.3%-351.1%8.9%-94.3%-1113.3%
Interest$0$1.0M$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-11.0M$-13.0M$-12.0M$-10.0M$-9.0M$-9.0M$-12.0M$-8.0M$-7.0M$2.0M$-5.0M$-153.0M
Tax$0$0$0$0$0$0$0$0$0$24.0M$0$0
Net Profit$-11.0M$-13.0M$-12.0M$-10.0M$-9.0M$-9.0M$-12.0M$-8.0M$-7.0M$2.0M$-5.0M$-153.0M
EPS$-7.20$-8.40$-7.50$-6.00$-5.10$-3.90$-5.10$-2.66$-2.21$0.43$-1.08$-24.14

Over the 10 years reported for Cue Biopharma, Inc., cash stood at $27.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.85 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$16.0M$67.0M$45.0M$72.0M$100.0M$83.0M$91.0M$62.0M$32.0M$42.0M
Current Assets$15.0M$65.0M$41.0M$61.0M$88.0M$68.0M$77.0M$51.0M$25.0M$37.0M
Cash$15.0M$64.0M$21.0M$44.0M$75.0M$64.0M$52.0M$49.0M$22.0M$27.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$1.0M$1.0M$3.0M$0$2.0M$1.0M$7.0M
Fixed Assets$1.0M$2.0M$3.0M$7.0M$9.0M$12.0M$11.0M$7.0M$5.0M$4.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$19.0M$15.0M$10.0M$0$25.0M$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$1.0M$5.0M$11.0M$17.0M$21.0M$18.0M$26.0M$24.0M$15.0M$16.0M
Current Liabilities$1.0M$5.0M$6.0M$12.0M$16.0M$13.0M$12.0M$17.0M$14.0M$13.0M
Borrowings$0$3.0M$0$6.0M$7.0M$12.0M$19.0M$15.0M$9.0M$4.0M
Other Liabilities$1.0M$3.0M$11.0M$11.0M$13.0M$6.0M$6.0M$10.0M$6.0M$12.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$15.0M$62.0M$34.0M$55.0M$79.0M$65.0M$66.0M$37.0M$17.0M$26.0M

For Cue Biopharma, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $22.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-6.0M$-12.0M$-26.0M$-31.0M$-32.0M$-39.0M$-42.0M$-40.0M$-36.0M$-22.0M
Investing Cash Flow$-1.0M$-2.0M$-41.0M$3.0M$4.0M$8.0M$-25.0M$25.0M$0$0
Financing Cash Flow$-1.0M$-4.0M$0$2.0M$2.0M$2.0M$4.0M$0$0$0
Net Cash Flow$9.0M$49.0M$-43.0M$23.0M$31.0M$-10.0M$-13.0M$-3.0M$-26.0M$5.0M
Free Cash Flow$-6.0M$-13.0M$-28.0M$-31.0M$-33.0M$-40.0M$-42.0M$-40.0M$-36.0M$-22.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.85
FCF Yield-27.01%
Quick Ratio1.25
Interest Coverage-730.70
Return 1Y42.69%
Return 3Y-77.55%
Return 5Y-90.15%

Cue Biopharma, Inc. (CUE) financials — frequently asked questions

What is Cue Biopharma, Inc.'s annual revenue?

Cue Biopharma, Inc. (CUE) reported annual revenue of $27.0M in its most recent fiscal year.

What is Cue Biopharma, Inc.'s net profit?

Cue Biopharma, Inc. (CUE) reported a net loss of $27.0M in its most recent fiscal year.

What is CUE EV/EBITDA?

Cue Biopharma, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -1.85. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
CUE Overview CUE Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.